霍奇金淋巴瘤治疗新进展：第55届美国血液学会年会报道

Novel therapy for Hodgkin lymphoma： reports in the 55th ASH annual meeting

2013年第55届美国血液学会（ASH）年会针对霍奇金淋巴瘤（HL）进行了专题报道,包含早期放化疗治疗选择、靶向治疗进展及结节性淋巴细胞为主型的HL治疗现状等内容.文章强调HL的治疗需结合病程特点及评效结果制定个体化治疗计划,以兼顾近期有效率及远期生存率.靶向治疗的有效性以及结节性淋巴细胞为主型HL治疗策略尚需进一步临床试验数据支持.

The 55th ASH annual meeting published a special report about Hodgkin lymphoma,which mainly contains management of early-stage Hodgkin lymphoma,novel targeted therapy and the optimal treatment of lymphocyte-predominant Hodgkin lymphoma.The therapy of Hodgkin lymphoma should be individualized,in order to improve both PFS and OS.More clinical trials should be designed on the target therapy and the treatment strategy of nodular lymphocyte-predominant Hodgkin lymphoma.